Proactive Investors - Run By Investors For Investors

THC Global raises nearly $3 million to fund transition into full-scale medicinal cannabis production

The company is waiting final licencing and permitting approvals to begin manufacturing at its Canndeo site in Canada.
THC Global raises nearly $3 million to fund transition into full-scale medicinal cannabis production
THC shares last traded at 43 cents

THC Global Group Ltd (ASX:THC) has confirmed that the final amount raised in its share purchase plan conducted in April this year totalled $2.983 million from a total of 545 applicants.

The company yesterday issued 5.967 million fully paid ordinary shares at an issue price of 50 cents a share to conclude the purchase plan.

Funds raised will be used to progress THC’s Australian medicinal cannabis activities as it transitions to full-scale production, as well as general working capital.

READ: THC Global Group progresses core drivers of revenue growth

The Australian cannabis company is awaiting final licencing and permitting approvals for a Canadian facility now owned by subsidiary Canndeo, which it plans to progress to a full-scale operation as part of a farm-to-pharma business model.

Cultivation activities at the Canndeo research and development facility have started following receipt of the relevant permits.

A manufacturing licence for the site is likely to facilitate product validation and study trial production.

READ: THC Global’s Canadian division boosts revenue 22% in March quarter

In November last year, THC supplied Endoca CBD products to its first prescribed patients.

The supply verified THC Global’s pathway from manufacturer to patient under federal authorised prescriber and special access schemes and state regulations.

THC imports four products from Endoca’s range: Endoca’s CBD oil in 3% and 15% concentrations; and Endoca’s unique CBD-plus-CBDa oils, also in 3% and 15% concentrations.

The company is also exploring strategic opportunities in Asia.

View full THC profile View Profile

THC Global Group Ltd Timeline

Related Articles

dna strand
May 08 2019
The latest update reveals the company significant clinical and commercial milestones in sight
Scientists in a lab
January 31 2019
CEO Gary Phillips says Pharmaxis’ healthy cash balance gives it time to choose between in-house and partnering options.
antibodies
May 02 2019
Avacta is using Affimers to develop its own cancer therapy, but it also licenses the technology to other companies, including major pharma group ModernaTX and LG Chem Life Sciences

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use